ReCept Pharmacy to Distribute Otezla® (apremilast): The First FDA Approved Oral Medication for the Treatment of Psoriatic Arthritis for Adults PR Newswire FORT WORTH, Texas, April 14, 2014 FORT WORTH, Texas, April 14, 2014 /PRNewswire/ --ReCept announces that it is among a select group of specialty pharmacies selected by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule which works by blocking the enzyme phosphodiesterase 4 to reduce swelling in joints and improve physical function in a form of arthritis that afflicts psoriasis sufferers. Approved by the FDA on March 21, 2014 and available for dispensing on April 9, ReCept has immediate access to dispense Otezla® at initial launch. According to the National Psoriasis Foundation, approximately 10 to 30 percent of people with psoriasis will develop psoriatic arthritis. Psoriasis is the most prevalent chronic inflammatory disease in the U.S. Otezla® is the first oral therapy approved to treat active psoriatic arthritis. In clinical trials, Otezla® demonstrated the ability to reduce the signs and symptoms of psoriatic arthritis. Patients treated with Otezla® showed improvement in signs and symptoms of PsA, including tender and swollen joints and physical function, compared to placebo. As a specialty pharmacy, ReCept is committed to providing patients with optimal outcomes for psoriatic arthritis. Through the use of robust medications like Otezla® in combination with ReCept's 'making people feel better' clinical approach to patient management, patients are able to take full advantage of treatment and maximize clinical benefit. About ReCept Pharmacy As a leader in the Specialty Pharmacy industry in the Southwest, ReCept cares for patients throughout a regional network of pharmacies located in Texas. With over 35 years of experience in providing pharmacy care, ReCept employs a knowledgeable, dedicated clinical staff to manage patients with complex chronic conditions. ReCept specializes in serving patients and their treating physicians within the therapeutic classes of Autoimmune, Hepatitis, HIV, Oncology, Compounding and Pain Management. Taking a holistic approach to patient management, ReCept understands specific disease states, their treatments and the effects those treatments have on individual patients. An avid commitment to keep patients adherent and compliant with their treatment regimen is ongoing. The ReCept corporate mission is simple: "To make people feel better" and improve their overall quality of life. For additional information on ReCept Pharmacy, please visit: www.receptrx.com SOURCE ReCept Pharmacy Website: http://www.receptrx.com Contact: Daryl Newman, 1-972-632-7485, firstname.lastname@example.org
ReCept Pharmacy to Distribute Otezla® (apremilast): The First FDA Approved Oral Medication for the Treatment of Psoriatic
Press spacebar to pause and continue. Press esc to stop.